Stereotaxis (NYSEAMERICAN:STXS) Shares Down 2.5% - Should You Sell?

Stereotaxis Inc. (NYSEAMERICAN:STXS - Get Free Report)'s stock price was down 2.5% during mid-day trading on Friday . The company traded as low as $2.29 and last traded at $2.32. Approximately 399,166 shares were traded during mid-day trading, an increase of 17% from the average daily volume of 340,709 shares. The stock had previously closed at $2.38.

Stereotaxis Stock Performance

The company has a fifty day simple moving average of $2.18 and a 200-day simple moving average of $2.13. The company has a market capitalization of $191.78 million, a PE ratio of -7.19 and a beta of 1.44.

Institutional Investors Weigh In On Stereotaxis

Hedge funds and other institutional investors have recently made changes to their positions in the business. ProShare Advisors LLC increased its position in Stereotaxis by 53.6% during the fourth quarter. ProShare Advisors LLC now owns 15,913 shares of the company's stock worth $36,000 after buying an additional 5,556 shares during the period. XTX Topco Ltd acquired a new position in Stereotaxis during the first quarter worth approximately $37,000. Two Sigma Securities LLC acquired a new position in Stereotaxis during the fourth quarter worth approximately $54,000. Wells Fargo & Company MN increased its position in Stereotaxis by 53.7% during the fourth quarter. Wells Fargo & Company MN now owns 26,915 shares of the company's stock worth $61,000 after buying an additional 9,403 shares during the period. Finally, Cherry Creek Investment Advisors Inc. increased its position in Stereotaxis by 16.6% during the first quarter. Cherry Creek Investment Advisors Inc. now owns 40,866 shares of the company's stock worth $72,000 after buying an additional 5,825 shares during the period. Institutional investors and hedge funds own 45.35% of the company's stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.